MRA Advisory Group Invests $651,000 in Guardant Health, Inc. (NASDAQ:GH)

MRA Advisory Group purchased a new position in Guardant Health, Inc. (NASDAQ:GH - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 15,275 shares of the company's stock, valued at approximately $651,000.

Other large investors have also recently modified their holdings of the company. Vanguard Group Inc. raised its position in Guardant Health by 3.0% in the 4th quarter. Vanguard Group Inc. now owns 12,052,551 shares of the company's stock worth $368,205,000 after buying an additional 350,606 shares during the last quarter. Deep Track Capital LP raised its position in Guardant Health by 7.0% in the 4th quarter. Deep Track Capital LP now owns 6,419,566 shares of the company's stock worth $196,118,000 after buying an additional 419,006 shares during the last quarter. Two Sigma Advisers LP increased its position in shares of Guardant Health by 96.7% during the 4th quarter. Two Sigma Advisers LP now owns 2,315,600 shares of the company's stock valued at $70,742,000 after purchasing an additional 1,138,300 shares during the last quarter. Two Sigma Investments LP increased its position in shares of Guardant Health by 38.5% during the 4th quarter. Two Sigma Investments LP now owns 1,890,714 shares of the company's stock valued at $57,761,000 after purchasing an additional 525,368 shares during the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. increased its position in shares of Guardant Health by 19.4% during the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,464,213 shares of the company's stock valued at $44,732,000 after purchasing an additional 238,037 shares during the last quarter. Hedge funds and other institutional investors own 92.60% of the company's stock.

Guardant Health Price Performance

GH stock opened at $48.41 on Friday. The business has a 50-day moving average price of $42.82 and a 200 day moving average price of $40.87. The company has a market capitalization of $6.00 billion, a P/E ratio of -13.60 and a beta of 1.49. Guardant Health, Inc. has a 1-year low of $20.14 and a 1-year high of $52.92.

Guardant Health (NASDAQ:GH - Get Free Report) last released its quarterly earnings data on Wednesday, April 30th. The company reported ($0.49) earnings per share for the quarter, beating the consensus estimate of ($0.57) by $0.08. The firm had revenue of $203.47 million during the quarter, compared to the consensus estimate of $189.91 million. Guardant Health had a negative return on equity of 19,157.20% and a negative net margin of 59.05%. The firm's quarterly revenue was up 20.8% on a year-over-year basis. During the same period in the previous year, the company posted ($0.46) earnings per share. On average, analysts anticipate that Guardant Health, Inc. will post -2.9 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the stock. The Goldman Sachs Group upped their price target on shares of Guardant Health from $49.00 to $56.00 and gave the company a "buy" rating in a research report on Friday, February 21st. Stifel Nicolaus increased their target price on shares of Guardant Health from $53.00 to $60.00 and gave the stock a "buy" rating in a report on Thursday, May 1st. Piper Sandler reissued an "overweight" rating and issued a $60.00 target price (up from $50.00) on shares of Guardant Health in a report on Tuesday, May 6th. Raymond James reissued an "outperform" rating and issued a $59.00 target price (up from $39.00) on shares of Guardant Health in a report on Friday, February 21st. Finally, Guggenheim reissued a "buy" rating and issued a $56.00 target price on shares of Guardant Health in a report on Monday, February 24th. Twenty investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock has an average rating of "Buy" and an average price target of $53.29.

Insider Activity at Guardant Health

In other news, CEO Amirali Talasaz sold 106,784 shares of the stock in a transaction on Thursday, May 1st. The stock was sold at an average price of $49.01, for a total transaction of $5,233,483.84. Following the completion of the transaction, the chief executive officer now directly owns 2,202,672 shares in the company, valued at approximately $107,952,954.72. This represents a 4.62% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In the last ninety days, insiders sold 107,232 shares of company stock valued at $5,252,559. 6.10% of the stock is owned by insiders.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.

Want to see what other hedge funds are holding GH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Guardant Health, Inc. (NASDAQ:GH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.